![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF620 |
Gene summary for ZNF620 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF620 | Gene ID | 253639 |
Gene name | zinc finger protein 620 | |
Gene Alias | ZNF620 | |
Cytomap | 3p22.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6ZNG0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
253639 | ZNF620 | HCC1_Meng | Human | Liver | HCC | 6.47e-19 | 1.62e-02 | 0.0246 |
253639 | ZNF620 | HCC1 | Human | Liver | HCC | 5.20e-09 | 9.63e-01 | 0.5336 |
253639 | ZNF620 | HCC2 | Human | Liver | HCC | 3.66e-15 | 1.77e+00 | 0.5341 |
253639 | ZNF620 | HCC5 | Human | Liver | HCC | 1.71e-09 | 1.46e+00 | 0.4932 |
253639 | ZNF620 | S014 | Human | Liver | HCC | 2.14e-03 | 2.10e-01 | 0.2254 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF620 | SNV | Missense_Mutation | novel | c.951C>A | p.Phe317Leu | p.F317L | Q6ZNG0 | protein_coding | deleterious(0) | benign(0.299) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ZNF620 | insertion | Frame_Shift_Ins | novel | c.202_203insCCAGG | p.Leu68ProfsTer34 | p.L68Pfs*34 | Q6ZNG0 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ZNF620 | insertion | In_Frame_Ins | novel | c.203_204insTCAAGCGATTCTTCTGCCTCA | p.Leu68_Pro69insGlnAlaIleLeuLeuProGln | p.L68_P69insQAILLPQ | Q6ZNG0 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ZNF620 | SNV | Missense_Mutation | rs375417538 | c.933N>A | p.Asn311Lys | p.N311K | Q6ZNG0 | protein_coding | tolerated(1) | benign(0) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF620 | SNV | Missense_Mutation | rs199758819 | c.167N>T | p.Thr56Met | p.T56M | Q6ZNG0 | protein_coding | deleterious(0) | benign(0.142) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF620 | SNV | Missense_Mutation | c.1040C>G | p.Ser347Cys | p.S347C | Q6ZNG0 | protein_coding | tolerated(0.12) | possibly_damaging(0.84) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF620 | SNV | Missense_Mutation | c.830N>G | p.Glu277Gly | p.E277G | Q6ZNG0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF620 | SNV | Missense_Mutation | c.218N>C | p.Asp73Ala | p.D73A | Q6ZNG0 | protein_coding | tolerated(0.08) | benign(0.133) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
ZNF620 | SNV | Missense_Mutation | c.815G>T | p.Arg272Ile | p.R272I | Q6ZNG0 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF620 | SNV | Missense_Mutation | novel | c.581N>G | p.Ile194Arg | p.I194R | Q6ZNG0 | protein_coding | tolerated(0.37) | benign(0.001) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |